NCT00937404View on ClinicalTrials.gov

Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants

PHASE1CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

August 4, 2009

Primary Completion Date

November 13, 2009

Study Completion Date

November 13, 2009

Conditions

Poliomyelitis

Interventions

BIOLOGICAL

Poliorix

All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.

Trial Locations (1)

Unknown

GSK Investigational Site, Wuzhou

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY